Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology
Market Cap
$1.89 Billion
CN¥13.85 Billion CNY
Market Cap Rank
#6109 Global
#894 in China
Share Price
CN¥29.59
Change (1 day)
-4.64%
52-Week Range
CN¥20.45 - CN¥31.37
All Time High
CN¥68.93
Categories
Companies in China Biotechnology
About

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more

Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Net Assets

Latest net assets as of September 2025: CN¥3.76 Billion CNY

Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) has net assets worth CN¥3.76 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.32 Billion) and total liabilities (CN¥1.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.76 Billion
% of Total Assets 70.74%
Annual Growth Rate 12.55%
5-Year Change 4.47%
10-Year Change 117.57%
Growth Volatility 33.73

Vcanbio Cell & Gene Engineering Corp Ltd - Net Assets Trend (1992–2024)

This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2024)

The table below shows the annual net assets of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2024.

Year Net Assets Change
2024-12-31 CN¥3.66 Billion -3.67%
2023-12-31 CN¥3.80 Billion +3.97%
2022-12-31 CN¥3.65 Billion +3.42%
2021-12-31 CN¥3.53 Billion +0.87%
2020-12-31 CN¥3.50 Billion +1.20%
2019-12-31 CN¥3.46 Billion +15.96%
2018-12-31 CN¥2.98 Billion +82.60%
2017-12-31 CN¥1.63 Billion -6.70%
2016-12-31 CN¥1.75 Billion +4.16%
2015-12-31 CN¥1.68 Billion +45.45%
2014-12-31 CN¥1.16 Billion +75.18%
2013-12-31 CN¥660.07 Million +134.45%
2012-12-31 CN¥281.54 Million +4.72%
2011-12-31 CN¥268.85 Million +10.13%
2010-12-31 CN¥244.13 Million +2.05%
2009-12-31 CN¥239.23 Million -6.66%
2008-12-31 CN¥256.31 Million +38.23%
2007-12-31 CN¥185.42 Million +0.75%
2006-12-31 CN¥184.04 Million +11.57%
2005-12-31 CN¥164.95 Million -46.78%
2004-12-31 CN¥309.95 Million -15.09%
2003-12-31 CN¥365.02 Million +2.01%
2002-12-31 CN¥357.83 Million -13.58%
2001-12-31 CN¥414.06 Million -4.58%
2000-12-31 CN¥433.95 Million +4.79%
1999-12-31 CN¥414.12 Million -0.56%
1998-12-31 CN¥416.47 Million +45.11%
1997-12-31 CN¥287.01 Million +14.71%
1996-12-31 CN¥250.20 Million +20.11%
1995-12-31 CN¥208.30 Million +21.74%
1994-12-31 CN¥171.11 Million +24.64%
1993-12-31 CN¥137.28 Million +64.94%
1992-12-31 CN¥83.23 Million --

Equity Component Analysis

This analysis shows how different components contribute to Vcanbio Cell & Gene Engineering Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5220.5% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥467.95 Million 13.02%
Other Comprehensive Income CN¥172.39 Million 4.80%
Other Components CN¥3.17 Billion 88.23%
Total Equity CN¥3.60 Billion 100.00%

Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Market Cap

The table below lists competitors of Vcanbio Cell & Gene Engineering Corp Ltd ranked by their market capitalization.

Company Market Cap
Polaris Bay Group Co Ltd
SHG:600155
 		$1.38 Billion
Zhejiang Medicine Co Ltd
SHG:600216
 		$1.38 Billion
SPAREBK 1 NORD-NORGE NK18
F:93S
 		$1.38 Billion
BRAZE INC. A DL-0001
F:K43
 		$1.38 Billion
Acadian Asset Management Inc
NYSE:AAMI
 		$1.38 Billion
Hebei Hengshui Laobaigan Liquor Co Ltd
SHG:600559
 		$1.38 Billion
Tabcorp Holdings Ltd
AU:TAH
 		$1.38 Billion
TIME Dotcom Bhd
KLSE:5031
 		$1.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vcanbio Cell & Gene Engineering Corp Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,684,062,269 to 3,595,087,564, a change of -88,974,705 (-2.4%).
  • Net income of 100,352,117 contributed positively to equity growth.
  • Dividend payments of 591,243 reduced retained earnings.
  • Share repurchases of 200,025,328 reduced equity.
  • Other comprehensive income increased equity by 14,227,346.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥100.35 Million +2.79%
Dividends Paid CN¥591.24K -0.02%
Share Repurchases CN¥200.03 Million -5.56%
Other Comprehensive Income CN¥14.23 Million +0.4%
Other Changes CN¥-2.94 Million -0.08%
Total Change CN¥- -2.42%

Book Value vs Market Value Analysis

This analysis compares Vcanbio Cell & Gene Engineering Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.75x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 53.95x to 3.75x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.55 CN¥29.59 x
1994-12-31 CN¥0.68 CN¥29.59 x
1995-12-31 CN¥0.83 CN¥29.59 x
1996-12-31 CN¥1.00 CN¥29.59 x
1997-12-31 CN¥1.10 CN¥29.59 x
1998-12-31 CN¥1.62 CN¥29.59 x
1999-12-31 CN¥1.58 CN¥29.59 x
2000-12-31 CN¥1.67 CN¥29.59 x
2001-12-31 CN¥1.44 CN¥29.59 x
2002-12-31 CN¥1.21 CN¥29.59 x
2003-12-31 CN¥1.21 CN¥29.59 x
2004-12-31 CN¥0.90 CN¥29.59 x
2005-12-31 CN¥0.26 CN¥29.59 x
2006-12-31 CN¥0.30 CN¥29.59 x
2007-12-31 CN¥0.27 CN¥29.59 x
2008-12-31 CN¥0.39 CN¥29.59 x
2009-12-31 CN¥0.42 CN¥29.59 x
2010-12-31 CN¥0.41 CN¥29.59 x
2011-12-31 CN¥0.47 CN¥29.59 x
2012-12-31 CN¥0.42 CN¥29.59 x
2013-12-31 CN¥1.39 CN¥29.59 x
2014-12-31 CN¥2.91 CN¥29.59 x
2015-12-31 CN¥4.03 CN¥29.59 x
2016-12-31 CN¥4.19 CN¥29.59 x
2017-12-31 CN¥4.37 CN¥29.59 x
2018-12-31 CN¥7.02 CN¥29.59 x
2019-12-31 CN¥7.42 CN¥29.59 x
2020-12-31 CN¥7.30 CN¥29.59 x
2021-12-31 CN¥7.40 CN¥29.59 x
2022-12-31 CN¥7.60 CN¥29.59 x
2023-12-31 CN¥7.96 CN¥29.59 x
2024-12-31 CN¥7.88 CN¥29.59 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vcanbio Cell & Gene Engineering Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.79%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 6.33%
  • • Asset Turnover: 0.30x
  • • Equity Multiplier: 1.46x
  • Recent ROE (2.79%) is below the historical average (4.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 14.67% 16.50% 0.67x 1.33x CN¥6.42 Million
1994 18.46% 17.84% 0.63x 1.65x CN¥14.38 Million
1995 10.16% 14.43% 0.37x 1.90x CN¥326.79K
1996 10.24% 10.05% 0.59x 1.72x CN¥593.19K
1997 10.54% 9.76% 0.49x 2.19x CN¥1.50 Million
1998 4.80% 10.44% 0.28x 1.66x CN¥-21.03 Million
1999 5.01% 19.89% 0.15x 1.66x CN¥-19.78 Million
2000 4.33% 9.01% 0.30x 1.62x CN¥-23.71 Million
2001 0.70% 0.85% 0.38x 2.17x CN¥-33.53 Million
2002 -20.95% -20.34% 0.55x 1.88x CN¥-93.54 Million
2003 1.04% 0.97% 0.51x 2.11x CN¥-27.05 Million
2004 -34.82% -27.85% 0.50x 2.48x CN¥-100.82 Million
2005 10.50% 1.90% 0.73x 7.60x CN¥317.96K
2006 10.20% 1.91% 0.70x 7.59x CN¥155.10K
2007 13.68% 3.03% 0.67x 6.78x CN¥3.19 Million
2008 31.05% 13.57% 0.44x 5.18x CN¥26.51 Million
2009 1.66% 0.69% 0.44x 5.47x CN¥-10.68 Million
2010 6.32% 3.28% 0.33x 5.82x CN¥-4.87 Million
2011 15.02% 10.07% 0.27x 5.43x CN¥7.83 Million
2012 9.49% 4.63% 0.24x 8.42x CN¥-754.66K
2013 1.44% 2.00% 0.24x 2.96x CN¥-42.93 Million
2014 3.43% 7.44% 0.20x 2.34x CN¥-67.78 Million
2015 13.41% 29.39% 0.25x 1.81x CN¥53.01 Million
2016 2.38% 4.52% 0.28x 1.89x CN¥-120.92 Million
2017 0.69% 0.78% 0.44x 1.99x CN¥-140.54 Million
2018 2.14% 4.49% 0.30x 1.60x CN¥-218.00 Million
2019 1.48% 3.58% 0.28x 1.46x CN¥-285.68 Million
2020 -3.71% -9.62% 0.27x 1.43x CN¥-468.37 Million
2021 4.48% 10.12% 0.31x 1.45x CN¥-191.03 Million
2022 3.18% 7.27% 0.29x 1.49x CN¥-242.59 Million
2023 2.89% 6.70% 0.29x 1.47x CN¥-261.95 Million
2024 2.79% 6.33% 0.30x 1.46x CN¥-259.16 Million

Industry Comparison

This section compares Vcanbio Cell & Gene Engineering Corp Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,722,009,584
  • Average return on equity (ROE) among peers: 7.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Vcanbio Cell & Gene Engineering Corp Ltd (600645) CN¥3.76 Billion 14.67% 0.41x $1.38 Billion
Shenzhen CAU Technology Co Ltd (000004) $183.33 Million -11.06% 0.92x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $966.91 Million 19.23% 0.71x $1.03 Billion
Nanhua Bio Medicine Co Ltd (000504) $387.30 Million 7.50% 0.60x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $248.75 Million
Chengzhi Shareholding Co Ltd (000990) $1.65 Billion 1.65% 0.84x $860.44 Million
Hualan Biological EngineeringInc (002007) $4.84 Billion 16.95% 0.08x $2.01 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.20 Billion 4.62% 0.66x $793.09 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $763.33 Million 17.77% 0.08x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $1.81 Billion 11.12% 0.67x $414.37 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $3.77 Billion 15.42% 0.67x $347.52 Million